MONOVISC®
MONOVISC® is a single injection of ultra-pure hyaluronan for the treatment of knee, hip, shoulder and ankle osteoarthritis.
1,650+ Annual applications in Austria
Quick and long-lasting pain relief
Outperforms conventional viscosupplements by stopping the wear process and allowing you to return to everyday life quickly.
Unique cross-linking process
Long-lasting lubrication and demonstrably improved joint mobility thanks to the patented cross-linking process.
Proven effectiveness and safety
Efficacy and safety confirmed by FDA studies with a low rate of side effects.
Indications of MONOVISC®:
Osteoarthritis in knee, hip, shoulder
& ankle
MONOVISC® is an FDA-approved viscosupplement made from ultra-pure, high-molecular hyaluronan, a natural lubricant for healthy joints. This non-avian product provides early and long-lasting pain relief through a single, highly concentrated injection. Its convenient 4 ml packaging makes it easy for doctors to use and improves comfort for patients.
Results of treatment with MONOVISC®
Joint pain relief
Has an analgesic effect, especially for movement pain.
Improving flexibility
Reduces morning stiffness & increases joint flexibility over the course of the day.
Reduction of swelling
Reduces inflammation and swelling
Reduction of joint noises
Improves lubrication & minimizes joint noises.
FDA study: Better WOMAC results with MONOVISC®
The clinical trial for MONOVISC® approval, which was reviewed by the FDA, provides good results regarding the safety and purity of the product. 369 patients were examined over a period of six months to evaluate the tolerability and effectiveness of MONOVISC®. Here are the key findings:
Improved and long-lasting effect
The WOMAC is a self-assessment questionnaire for patients and offered the best results in this study compared to other preparations.
Low side effect rate
Only 2.2% of patients reported mild reactions at the injection site. This is in contrast to a comparable product with a higher molecular weight, which has a side effect rate of 5.7%.
High degree of purity
Monovisc® is characterized by a particularly high degree of purity. It is produced using a biotechnological fermentation process and contains a high-purity and sterile hyaluronic acid solution.
High active ingredient content compared to other preparations
MONOVISC® provides a high active ingredient content compared to other cross-linked one-shot preparations available on the market. A 4 ml injection contains 88 mg hyaluronic acid at a concentration of 22 mg/ml.
Benefits for doctors
Easy application
The ergonomically optimized syringe and the option to complete the treatment with just one injection make it easier for doctors to use.
Long-lasting effects
The patented cross-linking process ensures that hyaluronic acid stays in the joint for an extended period of time.
Scientifically proven
The FDA approval based on a placebo-controlled, randomized, double-blind, multicenter study provides doctors with a solid scientific basis for using MONOVISC®.
Maximum safety
With just one injection required per treatment cycle and a low side effect rate of 2.2%, MONOVISC® offers a safe treatment option, supported by over 10 years of therapeutic experience.
Benefits for patients
Long-lasting effect
The improved retention time of hyaluronic acid in the knee joint provides long-lasting pain relief and improved mobility.
Single injection
The treatment only requires a single injection per treatment cycle.
Quick pain relief
Patients benefit from rapid pain reduction and a long-lasting pain-free phase thanks to the highly concentrated injection of MONOVISC®.
Low risk of side effects
With a very low rate of mild reactions at the injection site, MONOVISC® offers low-side effects treatment, which increases patients' sense of safety.
Product video
MONOVISC® studies
Downloads
Frequently asked questions
Here you can find frequently asked questions about MONOVISC®
- Syringe phobic
- (competitive athlete)
- Expect quick results
- Has little time and leads an active life
- Values high quality
MONOVISC® is suitable for treating osteoarthritis in all synovial joints.
MONOVISC® treatment requires only a single injection.
The components of MONOVISC® include a 4 ml volume injection containing 88 mg of cross-linked hyaluronic acid.
The goods can be sent by e-mail, in the office, by telephone, by our sales force or by fax
be ordered. Please enter the delivery and billing address as well as the
select the desired delivery time frame.
Orders placed within the following times will be delivered the next working day:
Monday to Thursday: 8:00 a.m. to 2:30 p.m.
Friday: 8:00 a.m. to 11:30 a.m.
